Atossa Therapeutics, Inc. ATOS
We take great care to ensure that the data presented and summarized in this overview for ATOSSA THERAPEUTICS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ATOS
View all-
Black Rock Inc. New York, NY9.2MShares$8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.59MShares$5.73 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.85MShares$2.48 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.86MShares$1.61 Million0.0% of portfolio
-
State Street Corp Boston, MA1.73MShares$1.5 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL974KShares$847,3780.0% of portfolio
-
Squarepoint Ops LLC New York, NY479KShares$416,7290.0% of portfolio
-
Ubs Group Ag455KShares$396,1850.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA440KShares$383,0910.0% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA423KShares$367,6460.0% of portfolio
Latest Institutional Activity in ATOS
Top Purchases
Top Sells
About ATOS
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
Insider Transactions at ATOS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 21
2025
|
Steven C Quay President & CEO |
BUY
Open market or private purchase
|
Direct |
11,239
+44.71%
|
$0
$0.88 P/Share
|
|
Mar 26
2025
|
H. Lawrence Remmel |
BUY
Open market or private purchase
|
Direct |
10,000
+49.37%
|
$0
$0.7 P/Share
|
|
Apr 10
2024
|
Jonathan Finn |
BUY
Open market or private purchase
|
Direct |
25,000
+50.0%
|
$25,000
$1.77 P/Share
|
|
Nov 15
2023
|
Gregory L Weaver Former EVP, CFO, & Director |
SELL
Open market or private sale
|
Direct |
50,000
-99.89%
|
$0
$0.65 P/Share
|
|
Jun 20
2023
|
Gregory L Weaver Former EVP, CFO, & Director |
BUY
Open market or private purchase
|
Direct |
50,000
+49.97%
|
$0
$0.97 P/Share
|
|
Jul 02
2021
|
Gregory L Weaver Former EVP, CFO, & Director |
SELL
Open market or private sale
|
Direct |
107,497
-100.0%
|
$537,485
$5.58 P/Share
|
|
Jul 02
2021
|
Gregory L Weaver Former EVP, CFO, & Director |
SELL
Payment of exercise price or tax liability
|
Direct |
57,084
-34.68%
|
$342,504
$6.4 P/Share
|
|
Jul 02
2021
|
Gregory L Weaver Former EVP, CFO, & Director |
BUY
Exercise of conversion of derivative security
|
Direct |
164,581
+39.91%
|
$493,743
$3.06 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 21.2K shares |
|---|